()
 

Overview

Masimo (Nasdaq: MASI - News) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate that Masimo SET provides the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures carboxyhemoglobin (SpCO), methemoglobin (SpMet), and pleth variability index (PVI), in addition to oxyhemoglobin (SpO2), perfusion ...

Contact Information

40 Parker
Irvine, CA 92618

tel: 949-297-7000
fax: 949-297-7001
http://www.masimo.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Medical Appliances & Equipment
Market Cap: $1.9B




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.